Skip to main content
. Author manuscript; available in PMC: 2018 May 1.
Published in final edited form as: J Am Coll Surg. 2018 Jan 10;226(4):434–443. doi: 10.1016/j.jamcollsurg.2017.12.027

Table 2. Complications after Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.

Clavien Dindo arm of study
Frequency Mitomycin 40 mg via IPHC, n (%), n=61 Oxaliplatin 200 mg/m2 via IPHC, n (%), n=60 Total
 0 7 (11.5) 1 (1.7) 8
 I 5 (8.20) 14 (23.3) 19
 II 29 (47.5) 25 (41.7) 54
 III 0 (0.00) 1 (1.7) 1
 IIIa 9 (14.8) 9 (15.0) 18
 IIIb 3 (4.9) 4 (6.7) 7
 IV 1 (1.6) 1 (1.7) 2
 IVa 4 (6.6) 1 (1.7) 5
 IVb 1 (1.6) 1 (1.7) 2
 V 1 (1.6) 3 (5.0) 6

IPHC, intraperitoneal hyperthermic chemotherapy.